Fish mesonephric model of polycystic kidney disease in medaka (Oryzias latipes) pc mutant

Fish mesonephric model of polycystic kidney disease in medaka (Oryzias latipes) pc mutant.BackgroundPolycystic kidney disease (PKD) is a common hereditary disease. A number of murine and zebrafish mutants have been generated and used for the study of PKD as metanephric and pronephric models, respectively. Here, we report a medaka (Oryzias latipes) mutant that develops numerous cysts in the kidney in adulthood fish in an autosomal-recessive manner as a mesonephric model of PKD.MethodsThe phenotypes of the medaka pc mutant were described in terms of morphologic, histologic, and ultrastructural features. The pc see-through stock was produced by crossing a pc mutant and a fish from the see-through stock and used for observing the kidney through the transparent body wall of a live fish.ResultsThe mutant developed bilateral massive enlargement of the kidney in adulthood. They sexually matured normally within 2 months of age and died within 6 months of age. The affected kidney was occupied by numerous, fluid-filled cysts, which were lined by attenuated squamous epithelial cells. Developmentally, cystic formation began in the pronephros in 10-day-old fry and in the mesonephros in 20-day-old fry at the microscopic level. The pc see-through stock was useful in observing disease progression in live fish.ConclusionThe kidney disorder that develops in the medaka pc mutant is a mesonephric counterpart of PKD, particularly an autosomal-dominant PKD, based on its morphologic, histologic, and ultrastructural features, and slow progression

Scribing of Ceramie Circuit Board with Q-Switched Nd：YAG Laser

Scribing of copper coated alumina ceramic board with Q-switched YAG laser used for the maskless direct patterning of circuit　board is experimentally investigated, which leads to efficient production of trial circuit board. Better dividing of alumina circuit board 655μm in thickness can be attained by the scribing of about 100μm depth. Higher repetition frequency of laser irradiation leads to smaller notch angle and lower breaking load

Energetic Advantage of Phosphodiesterase III Inhibitors in the Failed Heart after Global Ischemia

We evaluated the ventricular mechanical effects of PhosphodiesteraseIII (PDEIII) inhibitors in the failed heart after global ischemia induced by ventricular fibrillation (VF) using the left ventricular pressure-volume relationship (PVR). In 14 anesthetized open-chest dogs, left ventricular PVR was measured using a conductance catheter. Under administration of milrinone (MIL, n=7) and olprinone (OLP, n=7), the slopes of the LV end-systolic pressure-volume (Emax), arterial end-systolic pressure-stroke volume relations (Ea), ventriculoarterial coupling (Ea/Emax) and preload recruitable stroke work (PRSW) were obtained to evaluate changes in LV performance. The duration of VF was 1 min without cardiopulmonary bypass (CPB). OLP and MIL significantly increased the Emax and PRSW values in the failed heart after VF, and there was no dose-effect relationship at MIL doses of 0.25 to 0.75ﾎｼg/kg/min or at OLP doses of 0.1 to 0.3ﾎｼg/kg/min. The Ea/Emax value after VF was significantly lower in the presence of OLP or MIL than in the absence of these drugs (-45.3% with OLP and -46.5% with MIL). The results indicate that in the heart after transient global ischemia, both OLP and MIL improve hemodynamic and mechanical states in terms of ventriculoarterial coupling

A dual functional peptide carrying in vitro selected catalytic and binding activities

When minimal functional sequences are used, it is possible to integrate multiple functions on a single peptide chain, like a “single stroke drawing”.</p

Clinical characteristics, management strategies and outcomes of patients with recurrent venous thromboembolism in the real world

There is a paucity of data on management strategies and clinical outcomes after recurrent venous thromboembolism (VTE). In a multicenter registry enrolling 3027 patients with acute symptomatic VTE, the current study population was divided into the following 3 groups: (1) First recurrent VTE during anticoagulation therapy (N = 110); (2) First recurrent VTE after discontinuation of anticoagulation therapy (N = 116); and (3) No recurrent VTE (N = 2801). Patients with first recurrent VTE during anticoagulation therapy more often had active cancer (45, 25 and 22%, P < 0.001). Among 110 patients with first recurrent VTE during anticoagulation therapy, 84 patients (76%) received warfarin at recurrent VTE with the median prothrombin time-international normalized ratio (PT-INR) value at recurrent VTE of 1.6, although patients with active cancer had a significantly higher median PT-INR value at recurrent VTE compared with those without active cancer (2.0 versus 1.4, P < 0.001). Within 90 days after recurrent VTE, 23 patients (20.9%) during anticoagulation therapy and 24 patients (20.7%) after discontinuation of anticoagulation therapy died. Active cancer was a major cause of recurrent VTE during anticoagulation therapy as a patient-related factor, while sub-optimal intensity of anticoagulation therapy was a major cause of recurrent VTE during anticoagulation therapy as a treatment-related factor, particularly in patients without active cancer

RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS

Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone–collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.Shimizu Mikito, Shiraishi Naoyuki, Tada Satoru, et al. RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS. Science Advances 9, 686 (2023); https://doi.org/10.1126/sciadv.adg3193

Design and Synthesis of Binding Growth Factors

Growth factors play important roles in tissue regeneration. However, because of their instability and diffusible nature, improvements in their performance would be desirable for therapeutic applications. Conferring binding affinities would be one way to improve their applicability. Here we review techniques for conjugating growth factors to polypeptides with particular affinities. Conjugation has been designed at the level of gene fusion and of polypeptide ligation. We summarize and discuss the designs and applications of binding growth factors prepared by such conjugation approaches

Development of an atmospheric Cherenkov imaging camera for the CANGAROO-III experiment

A Cherenkov imaging camera for the CANGAROO-III experiment has been developed for observations of gamma-ray induced air-showers at energies from 10$^{11}$ to 10$^{14}$ eV. The camera consists of 427 pixels, arranged in a hexagonal shape at 0.17$^\circ$ intervals, each of which is a 3/4-inch diameter photomultiplier module with a Winston-cone--shaped light guide. The camera was designed to have a large dynamic range of signal linearity, a wider field of view, and an improvement in photon collection efficiency compared with the CANGAROO-II camera. The camera, and a number of the calibration experiments made to test its performance, are described in detail in this paper.Comment: 25 pages, 29 figures, elsart.cls, to appear in NIM-

Design and Synthesis of Binding Growth Factors

Growth factors play important roles in tissue regeneration. However, because of their instability and diffusible nature, improvements in their performance would be desirable for therapeutic applications. Conferring binding affinities would be one way to improve their applicability. Here we review techniques for conjugating growth factors to polypeptides with particular affinities. Conjugation has been designed at the level of gene fusion and of polypeptide ligation. We summarize and discuss the designs and applications of binding growth factors prepared by such conjugation approaches